Findings of a hospital surveillance-based outcome evaluation study for Clostridium difficile-associated colitis.
We completed a prospective study of 164 patients involved in a Clostridium difficile surveillance programme, evaluating a range of variables such as disease severity, treatment regimen and known clinical risk factors, for their effect on case lethality. The aim of this study was to determine if there are any additional clinical variables worth considering for inclusion in the therapeutic decision-making process. Beyond common risk factors, secondary immunodeficiencies such as diabetes mellitus, malignancy, autoimmune disease, immunosuppressive therapy and chronic hepatitis were assessed. Overall case lethality was 23%. There was a suggestion that regular proton pump inhibitor use in past medical history might be associated with greater lethality. Immunosuppressive therapy within 1 month before the onset of diarrhoea was associated with a significant four-fold lethality increase. This last finding may have the potential to further improve therapeutic judgement if used as an explicit component of a revised scoring system. In relation to Clostridium difficile-associated colitis, immunosuppressive therapy as a red flag entity, as described here, has not been previously published.
Kenezy Gyula Hospital and Outpatient Facility, Debrecen, Hungary.
I
I
Varkonyi
E
E
Rakoczi
O
O
Misak
E
E
Komaromi
L
L
Kardos
Z
Z
Lampe
Z
Z
Szilvassy
D000368:Aged; D000369:Aged, 80 and over; D016360:Clostridioides difficile / Q000302:isolation & purification*; D004761:Enterocolitis, Pseudomembranous / Q000382:microbiology / Q000401:mortality*; D062665:Epidemiological Monitoring; D005260:Female; D006761:Hospitals; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D007154:Immune System Diseases / Q000150:complications / Q000453:epidemiology*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D012720:Severity of Illness Index
D007166:Immunosuppressive Agents; D054328:Proton Pump Inhibitors
Clostridium difficile; colitis; hospital surveillance; immunosuppression; prognosis